Human trial started on promising universal Influenza Vaccine

The early-stage human trial is set to enlist 24 healthy volunteers, carefully selected between the ages of 18 and 50.

September 18, 2023

123

a group of pills falling — Picture: Pixabay

Table of Contents

Last Updated on October 15, 2024 by The Health Master

Human trial

In a significant stride towards a universal influenza vaccine, the U.S. National Institutes of Health (NIH) has kicked off an early-stage Human trial of their groundbreaking experimental vaccine, FluMos-v2.

This vaccine aims to combat six strains of the influenza virus, offering a new level of protection against both influenza A and B viruses.

The Quest for an Ideal Universal Influenza Vaccine

The NIH’s ambitious venture into developing a universal influenza vaccine is fueled by the aspiration to reduce the frequency of vaccinations and broaden the spectrum of protection against diverse strains of the influenza virus.

Hugh Auchincloss, the NIAID’s acting director, said, “With each new universal influenza vaccine candidate and clinical trial, we take another step toward that goal.”

Click for more articles on Human Trial

FluMos-v2: A Breakthrough Vaccine Candidate

FluMos-v2 is meticulously crafted to target four strains of influenza A virus and two strains of influenza B virus.

This promising vaccine, developed by the proficient researchers at NIAID’s Vaccine Research Center, holds the potential to revolutionize influenza prevention.

Enrolling the Pioneers

The early-stage human trial is set to enlist 24 healthy volunteers, carefully selected between the ages of 18 and 50.

These pioneers will receive two intramuscular injections of FluMos-v2 at a 16-week interval, allowing researchers to observe and analyze the vaccine’s efficacy and safety profile.

Click for more articles on Influenza Vaccine

Moderna’s Strides in Flu Vaccine Development

In a parallel development, COVID vaccine manufacturer Moderna announced a breakthrough in their flu vaccine research.

Their vaccine demonstrated a notably heightened immune response against all four A and B strains of the influenza virus in a late-stage trial, surpassing the effectiveness of conventional flu shots.

Conclusion:

The NIH’s commitment to developing a universal influenza vaccine is marked by the initiation of the FluMos-v2 human trial, a beacon of hope for a more comprehensive defense against influenza.

Coupled with Moderna’s encouraging advancements, the landscape of influenza prevention is poised for a transformative shift.

These endeavors signify a significant stride towards a future where protection against influenza is more potent and accessible than ever before.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.